Where should the drug industry go to find new ideas? In the first of two features, Alison Abbott asks if the future lies in systems biology -- a field that attempts to piece together 'everything'. In the second, David Cyranoski looks at drug companies' attraction to China.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
BMC Medical Genomics Open Access 08 January 2009
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhang, H., Li, X. J., Martin, D. B. & Aebersold, R. Nature Biotechnol. 21, 660–666 (2003).
Hendriks, B. S. et al. IEE Proc. Syst. Biol. 153, 22–33 (2006).
Chen, Y. et al. Nature 452, 429–435 (2008).
Emilsson, V. et al. Nature 452, 423–428 (2008).
Additional information
Alison Abbott is Nature's senior European correspondent.
Related links
Related links
Related external links
Rights and permissions
About this article
Cite this article
Abbott, A. Pharmaceutical futures: A fiendish puzzle. Nature 455, 1164–1167 (2008). https://doi.org/10.1038/4551164a
Published:
Issue Date:
DOI: https://doi.org/10.1038/4551164a
